Speciality Medicines Limited is coming out with a ₹29.14 crore SME IPO on the BSE SME platform, offering 23.50 lakh fresh equity shares in a price band of ₹117–₹124 per share, to fund an R&D centre, international product registrations, marketing, and working capital for its speciality pharma business.
Speciality Medicines IPO – Key Details
|
Item |
Details |
|
IPO Type |
SME IPO (100% fresh issue) on BSE SME |
|
Issue Size |
23,50,000 shares ≈ ₹29.14 crore |
|
Price Band |
₹117–₹124 per share (FV ₹10) |
|
IPO Dates |
Opens 20 March 2026 – Closes 24 March 2026 |
|
Allotment |
25–26 March 2026 (basis of allotment) |
|
Refunds / Demat Credit |
27 March 2026 |
|
Listing Date |
29–30 March 2026 on BSE SME |
|
Lot Size |
1,000 shares per lot (min 2 lots for retail ≈ ₹2.34–₹2.48 lakh) |
|
Minimum Investment |
₹2,34,000–₹2,48,000 (2,000 shares at band) |
|
Issue Structure |
100% fresh issue – no OFS |
Business Overview & Use of IPO Proceeds
What Speciality Medicines Does
- Markets and distributes specialised pharmaceutical products used to treat serious and long-term conditions like cancer (oncology), immune disorders (immunology), neurological diseases, and rare illnesses.
- Offers a wide product basket: tablets, capsules, syrups, injections, inhalers across multiple therapeutic areas.
- Operates with a dual business model:
- Gets medicines manufactured via third-party manufacturers (own brands) and sells domestically and overseas.
- Also sources medicines from manufacturers/markets and distributes to customers in India and international markets.
Geographical Reach
- Presence across 20+ Indian states and select international markets, leveraging its distribution network and customer relationships.
Use of IPO Proceeds – ₹29.14 crore (100% fresh)
|
Purpose |
Amount (₹ crore) |
% of Issue |
|
R&D Centre |
12.67 |
43.48% |
|
Product registration (international markets) |
2.99 |
10.26% |
|
Marketing & brand promotion |
2.00 |
6.86% |
|
Working capital |
8.00 |
27.00% |
|
General corporate purposes |
3.48 |
11.94% |
R&D and international registrations clearly show a growth‑oriented deployment, not promoter exit.
Financial Snapshot (Last 3 Years)
From Economic Times / SME details (₹ crore):
|
FY End (Mar) |
2023 |
2024 |
2025 |
|
Net Sales |
23.24 |
27.52 |
58.27 |
|
Total Income |
23.26 |
27.66 |
58.54 |
|
Total Expenditure |
19.68 |
22.26 |
49.18 |
|
EBITDA |
3.59 |
5.39 |
9.36 |
|
EBIT |
3.29 |
5.16 |
9.16 |
|
Profit Before Tax (EBT) |
2.95 |
4.56 |
8.69 |
|
PAT |
1.69 |
2.93 |
8.61 |
- Revenue more than doubled from ₹27.52 crore (FY24) to ₹58.27 crore (FY25).
- PAT grew ~3x from ₹2.93 crore to ₹8.61 crore over the same period.
Strengths of Speciality Medicines IPO
- Focus on speciality medicines for complex, chronic and serious diseases (oncology, immunology, neurology, rare diseases) where entry barriers and margins are typically higher.
- Diverse product portfolio across multiple therapeutic areas and dosage forms (tablets, injections, inhalers, syrups), reducing dependence on any single molecule or form.
- Dual business model (third‑party manufacturing + distribution) allows asset‑light scaling and flexibility in sourcing and marketing.
- International presence via product exports and registrations enhances growth potential beyond the domestic market.
- Strong recent financial growth with net sales more than doubling and PAT tripling between FY23 and FY25, indicating improving scale and profitability.
Key Risks of Speciality Medicines IPO
- Dependence on third‑party manufacturers for a large part of its product supply, exposing it to quality, compliance, and capacity risks outside its direct control.
- High customer concentration – significant revenue share from a few key customers could hurt top line if any relationship weakens.
- Strict quality and regulatory requirements in pharma may lead to order cancellations, product recalls, or penalties if standards slip.
- Ongoing legal proceedings involving a promoter, which could pose reputation and governance risks if outcomes are adverse.
- Exposure to supply disruptions and price volatility in pharma supply chains (APIs, intermediates), which can compress margins and impact availability.
How To Apply for the IPO ?
- Login or Open demat account with JM Financial Services / JM PRO app: Open the JM PRO app or JM Financial Services website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of IPO?
Steps to check IPO allotment status on JM Pro app:
- Log in to the JM Pro app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
JM Financial Services will notify you of your IPO allotment status via push notification and email
FAQs
1. What are the Speciality Medicines IPO dates, price band and lot size?
The Speciality Medicines SME IPO opens on 20 March 2026 and closes on 24 March 2026, with a price band of ₹117–₹124 per share. The lot size is 1,000 shares, and retail investors typically must apply for at least 2 lots (2,000 shares), translating to a minimum investment of about ₹2.34–₹2.48 lakh.
2. How big is the Speciality Medicines IPO and what type of issue is it?
The IPO is a 100% fresh issue of 23.50 lakh equity shares, aggregating to about ₹29.14 crore at the upper band. There is no Offer for Sale (OFS), so all proceeds go to the company.
3. What will Speciality Medicines use the IPO money for?
The company plans to use the funds mainly for setting up an R&D centre (₹12.67 crore), product registrations in international markets (₹2.99 crore), marketing and brand promotion (₹2 crore), working capital (₹8 crore), and general corporate purposes (₹3.48 crore).
4. What kind of business and products does Speciality Medicines have?
Speciality Medicines focuses on specialised drugs for complex and long‑term conditions, including oncology, immunology, neurology and rare diseases. It sells medicines in forms like tablets, capsules, syrups, injections and inhalers, both under its own brands (via third‑party manufacturing) and as a distributor for other manufacturers in India and select global markets.
5. Is Speciality Medicines IPO suitable for long‑term investors or just for listing gains?
Being an SME IPO in speciality pharma with strong recent growth, focused R&D and global ambitions, it may appeal to high‑risk, long‑term investors who understand pharma and SME liquidity. However, risks like third‑party dependence, customer concentration, regulatory challenges and promoter legal proceedings mean investors should evaluate carefully and not treat it as a pure low‑risk listing play.
